EULAT Eradicate GBC

Launched by INSTITUT DE CANCÉROLOGIE STRASBOURG EUROPE · Dec 21, 2023

Keywords

ClinConnect Summary

The EULAT Eradicate GBC trial is studying gallbladder cancer (GBC) and gallstone disease to find better ways to predict and diagnose GBC early. Gallstones are common, especially in women, and they can increase the risk of developing gallbladder cancer. Currently, doctors mainly use imaging tests like ultrasounds and CT scans, along with more invasive procedures like biopsies and surgeries, to diagnose GBC. However, there are no reliable tests available yet that can predict the risk of developing this cancer early on. The main treatment for GBC is surgery, which works best when the cancer is caught in its early stages.

The trial is looking for participants aged 18 and older, specifically those with gallbladder cancer or precancerous conditions, as well as individuals scheduled for gallbladder surgery due to gallstones. Participants will help researchers identify factors that contribute to the development of GBC and explore genetic markers in various body fluids that could lead to better risk assessment and early diagnosis. If you join this trial, you’ll be contributing to important research that could improve how gallbladder cancer is detected and treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Cohort A. Patients with gallbladder cancer or dysplasia, both before and after the start of their anticancer treatment.
• • Cohort B. Patients with cholelithiasis before cholecystectomy (only patients scheduled for cholecystectomy will be recruited)
• • 2. Diagnosis confirmed in accordance with standard protocols of the participating hospitals
• • 3. Men and women aged 18 or over
• Exclusion Criteria:
• • 1. Any medical condition that present an unreasonable risk to the participant.
• • 2. Any psychiatric condition that interferes with understanding informed consent.